Evogene Ltd.
EVGNHealthcare|Biotechnology|IL
$0.27
-0.06 (-17.78%)
Tangible Book / Share
$0.47
Cash / Share
$0.76
Financials
Financial Snapshot
Market Cap
$2.3M
Enterprise Value
-$4.7M
Revenue (TTM)
$1.3M
Net Income (TTM)
-$9.1M
Cash & Investments
$9.4M
Net Cash
$7.3M
Free Cash Flow (TTM)
-$11.6M
Operating CF (TTM)
-$11.5M
Debt/Equity
-0.63
Cash Runway & Burn Rate
Cash on Hand
$9.4M
Quarterly Burn
$2.9M
Monthly Burn
$961.3K
Est. Runway
~3.2 quarters
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $88.1M | $71.8M | $54.5M | $46.9M | $48.2M | $53.9M | $35.4M | $31.1M | $15.3M | $13.0M | $9.4M | |
| Operating Cash Flow | -$11.7M | -$15.9M | -$15.2M | -$17.4M | -$19.5M | -$24.8M | -$23.7M | -$21.6M | -$19.7M | -$13.5M | -$11.5M | |
| Free Cash Flow | -$12.5M | -$16.5M | -$15.5M | -$18.3M | -$20.2M | -$25.6M | -$24.8M | -$22.4M | -$20.3M | -$13.6M | -$11.6M | |
| Capital Expenditure | -$808.0K | -$590.0K | -$374.0K | -$900.0K | -$682.0K | -$724.0K | -$1.2M | -$785.0K | -$626.0K | -$135.0K | -$28.7K | |
| Financing Cash Flow | $655.0K | $814.0K | $297.0K | $9.0M | $20.4M | $30.3M | $9.3M | $18.2M | $4.7M | -$6.6M | -$9.7M |
R&D Spending
R&D (TTM)
$6.3M
R&D Intensity
479.4%
R&D Growth vs Prior
-21.6%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.5M | $3.4M | $1.7M | $753.0K | $1.0M | $930.0K | $1.7M | $3.0M | $5.6M | $3.9M | $1.3M | |
| R&D Expense | $16.4M | $17.0M | $14.7M | $15.8M | $17.3M | $21.1M | $20.8M | $16.2M | $12.5M | $8.0M | $6.3M | |
| R&D % of Revenue | 250.8% | 502.4% | 840.6% | 2097.1% | 1662.2% | 2271.5% | 1241.3% | 543.1% | 224.3% | 207.5% | 479.4% | |
| SG&A | $5.6M | $5.5M | $5.6M | $5.8M | $8.0M | $10.0M | $10.4M | $7.5M | $9.0M | $5.8M | $5.4M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.5M | $3.4M | $1.7M | $753.0K | $1.0M | $930.0K | $1.7M | $3.0M | $5.6M | $3.9M | $1.3M | |
| Cost of Revenue | $5.6M | $2.8M | $1.5M | $334.0K | $574.0K | $767.0K | $909.0K | $1.5M | $2.4M | $4.1M | $2.9M | |
| Gross Profit | $901.0K | $536.0K | $295.0K | $419.0K | $466.0K | $163.0K | $766.0K | $1.5M | $3.2M | -$241.0K | -$1.6M | |
| R&D | $16.4M | $17.0M | $14.7M | $15.8M | $17.3M | $21.1M | $20.8M | $16.2M | $12.5M | $8.0M | $6.3M | |
| SG&A | $5.6M | $5.5M | $5.6M | $5.8M | $8.0M | $10.0M | $10.4M | $7.5M | $9.0M | $5.8M | $5.4M | |
| Operating Income | -$21.1M | -$21.9M | -$20.0M | -$21.2M | -$24.8M | -$31.0M | -$26.9M | -$22.2M | -$18.8M | -$14.0M | -$13.5M | |
| Interest Expense | $155.0K | $129.0K | $141.0K | $354.0K | $269.0K | $403.0K | $241.0K | $171.0K | $124.0K | $1.9M | $4.9M | |
| Pretax Income | -$19.6M | -$20.8M | -$20.8M | -$19.1M | -$26.2M | -$30.4M | -$29.8M | -$21.9M | -$14.8M | -$13.5M | -$15.6M | |
| Net Income | -$19.6M | -$20.8M | -$20.8M | -$18.1M | -$23.4M | -$27.8M | -$26.6M | -$23.9M | -$16.5M | -$8.5M | -$9.1M | |
| EPS (Diluted) | -0.77 | -0.81 | -0.81 | -0.70 | -0.64 | -0.68 | -6.46 | -5.23 | -2.89 | -1.08 | -0.91 | |
| EBITDA | -$18.8M | -$18.7M | -$18.8M | -$16.0M | -$23.2M | -$27.9M | -$27.0M | -$20.5M | -$13.4M | -$12.2M | -$12.6M | |
| Shares Out. (M) | 25.44 | 25.73 | 25.75 | 25.75 | 36.55 | 41.01 | 4.12 | 4.57 | 5.70 | 7.87 | 12.20 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $3.2M | $3.4M | $5.8M | $34.7M | $46.2M | $32.3M | $29.0M | $20.8M | $15.3M | $13.0M | $9.4M | |
| Short-Term Investments | $84.9M | $68.3M | $48.7M | $12.1M | $2.0M | $21.5M | $6.4M | $10.3M | $10.0K | $0.00 | $0.00 | |
| Total Current Assets | $89.5M | $72.8M | $55.5M | $49.0M | $51.8M | $56.9M | $37.8M | $34.5M | $21.6M | $15.6M | $10.9M | |
| Total Assets | $96.0M | $77.6M | $58.7M | $71.4M | $71.9M | $76.3M | $56.1M | $51.1M | $39.9M | $20.0M | $13.4M | |
| Total Current Liabilities | $5.2M | $4.7M | $5.4M | $5.7M | $9.7M | $6.9M | $5.6M | $6.9M | $18.7M | $3.4M | $3.0M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $10.1M | $10.4M | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $8.7M | $8.2M | $8.4M | $11.1M | $15.0M | $12.9M | $21.3M | $22.4M | $25.0M | $8.1M | $7.7M | |
| Stockholders' Equity | $87.3M | $69.4M | $50.1M | $50.1M | $46.0M | $53.7M | $27.9M | $12.1M | -$1.5M | -$82.0K | -$3.3M | |
| Retained Earnings | -$96.2M | -$117.0M | -$137.8M | -$155.9M | -$179.3M | -$207.1M | -$233.7M | -$257.6M | -$274.1M | -$282.6M | -$290.2M |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$11.7M | -$15.9M | -$15.2M | -$17.4M | -$19.5M | -$24.8M | -$23.7M | -$21.6M | -$19.7M | -$13.5M | -$11.5M | |
| Capital Expenditure | -$808.0K | -$590.0K | -$374.0K | -$900.0K | -$682.0K | -$724.0K | -$1.2M | -$785.0K | -$626.0K | -$135.0K | -$28.7K | |
| Free Cash Flow | -$12.5M | -$16.5M | -$15.5M | -$18.3M | -$20.2M | -$25.6M | -$24.8M | -$22.4M | -$20.3M | -$13.6M | -$11.6M | |
| Investing Cash Flow | $4.0M | $15.2M | $17.4M | $37.1M | $9.4M | -$20.4M | $13.3M | -$4.5M | $9.6M | $17.7M | $21.7M | |
| Financing Cash Flow | $655.0K | $814.0K | $297.0K | $9.0M | $20.4M | $30.3M | $9.3M | $18.2M | $4.7M | -$6.6M | -$9.7M | |
| Issuance of Stock | $186.0K | $683.0K | $9.0K | $10.0M | $18.7M | $29.6M | $21.0K | $8.4M | $123.0K | $4.3M | $4.3M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $0.00 | $0.00 | $0.00 | -$597.0K | -$639.0K | -$580.0K | $9.2M | -$836.0K | -$901.0K | -$526.0K | -$254.0K | |
| Stock Based Comp. | $2.9M | $2.2M | $1.7M | $1.6M | $4.1M | $2.6M | $1.2M | $1.9M | $1.8M | $654.0K | $155.0K | |
| Net Change in Cash | -$7.0M | $199.0K | $2.4M | $28.9M | $11.5M | -$13.9M | -$3.3M | -$8.2M | -$5.5M | -$2.3M | $990.0K |
Dilution Tracker
Shares Outstanding
9M
5-Year Share Growth
-78.5%
Stock Issuance (TTM)
$4.3M
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 25.44 | 25.73 | 25.75 | 25.75 | 36.55 | 41.01 | 4.12 | 4.57 | 5.70 | 7.87 | 12.20 | |
| Change vs Prior % | — | 1.1% | 0.1% | 0.0% | 41.9% | 12.2% | -90.0% | 10.9% | 24.7% | 38.2% | 54.9% | |
| Stock Issuance | $186.0K | $683.0K | $9.0K | $10.0M | $18.7M | $29.6M | $21.0K | $8.4M | $123.0K | $4.3M | $4.3M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $2.9M | $2.2M | $1.7M | $1.6M | $4.1M | $2.6M | $1.2M | $1.9M | $1.8M | $654.0K | $155.0K |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 13.8% | 15.9% | 16.9% | 55.6% | 44.8% | 17.5% | 45.7% | 50.0% | 57.3% | -6.3% | -123.9% | |
| Operating Margin % | -322.5% | -649.1% | -1144.2% | -2810.9% | -2386.0% | -3328.3% | -1608.4% | -745.5% | -337.2% | -364.2% | -1035.0% | |
| Net Margin % | -299.6% | -616.3% | -1188.2% | -2405.3% | -2247.5% | -2988.5% | -1590.3% | -800.8% | -295.6% | -220.2% | -694.2% | |
| EBITDA Margin % | -287.6% | -552.6% | -1074.0% | -2127.5% | -2231.7% | -2998.2% | -1612.5% | -688.5% | -239.6% | -316.6% | -961.4% | |
| FCF Margin % | -191.1% | -488.6% | -889.2% | -2425.5% | -1941.9% | -2748.7% | -1483.5% | -749.9% | -364.5% | -353.9% | -884.8% | |
| ROE % | -22.4% | -30.0% | -41.5% | -36.1% | -50.8% | -51.8% | -95.4% | -198.1% | 1136.1% | 10347.6% | 762.0% | |
| ROA % | -20.4% | -26.9% | -35.4% | -25.4% | -32.5% | -36.4% | -47.5% | -46.7% | -41.4% | -42.3% | -67.7% | |
| ROIC % | -23.2% | -30.1% | -37.5% | -31.8% | -39.4% | -44.0% | -52.4% | -49.4% | -58.5% | -81.0% | -113.7% | |
| R&D / Revenue % | 250.8% | 502.4% | 840.6% | 2097.1% | 1662.2% | 2271.5% | 1241.3% | 543.1% | 224.3% | 207.5% | 479.4% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -41.2% | -48.3% | -48.3% | -56.9% | 38.1% | -10.6% | 80.1% | 78.0% | 87.0% | -30.9% | |
| Gross Profit | -68.6% | -40.5% | -45.0% | 42.0% | 11.2% | -65.0% | 369.9% | 94.8% | 114.3% | -107.5% | |
| Operating Income | -17.7% | -4.1% | 8.9% | -5.9% | -17.2% | -24.7% | 13.0% | 17.5% | 15.4% | 25.4% | |
| Net Income | -13.8% | -6.4% | 0.4% | 12.7% | -29.1% | -18.9% | 4.2% | 10.4% | 31.0% | 48.5% | |
| EPS (Diluted) | -13.2% | -5.2% | 0.0% | 13.6% | 8.6% | -6.3% | -850.0% | 19.0% | 44.7% | 62.6% | |
| Operating Cash Flow | 5.8% | -36.2% | 4.8% | -14.5% | -12.4% | -27.3% | 4.7% | 8.9% | 8.7% | 31.5% | |
| Free Cash Flow | 13.3% | -32.1% | 6.0% | -17.6% | -10.6% | -26.6% | 2.8% | 10.0% | 9.1% | 32.9% | |
| R&D Expense | 13.5% | 3.5% | -13.5% | 7.5% | 9.5% | 22.2% | -1.6% | -22.1% | -22.8% | -36.1% | |
| SG&A Expense | -12.0% | -1.6% | 1.9% | 3.5% | 38.0% | 25.0% | 4.2% | -27.7% | 19.3% | -35.8% | |
| Total Assets | -14.8% | -19.2% | -24.4% | 21.6% | 0.8% | 6.1% | -26.4% | -9.0% | -22.0% | -49.7% | |
| Book Value / Share | -16.3% | -21.4% | -27.6% | 19.7% | -33.4% | -0.6% | 445.9% | -25.6% | -58.5% | -41.6% | |
| Debt | 0.0% | 0.0% | 0.0% | 0.0% | -17.9% | 9.4% | 347.0% | -3.6% | 11.9% | -82.9% | |
| Diluted Shares | 0.5% | 1.1% | 0.1% | 0.0% | 41.9% | 12.2% | -90.0% | 10.9% | 24.7% | 38.2% |
Valuation
P/E (TTM)At Loss
P/S1.94
10Y Low / Med / High1.91 / 233.60 / 1651.98
P/B-1.09
10Y Low / Med / High1.03 / 11.38 / 37.31
EV/EBITDA0.39
EV/Revenue-3.57
10Y Low / Med / High1.48 / 232.58 / 1609.88
P/FCFAt Loss
Intrinsic Value Models (per share)
Tangible Book / Share
$0.47
Net Current Assets / Share
$0.37
Graham Net-Net
$0.16
Cash / Share
$0.76
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -66.23 | -37.90 | -24.44 | -21.71 | -73.44 | -24.12 | -1.08 | -1.61 | -0.65 | -1.02 | -0.32 | |
| P/S Ratio | 198.42 | 233.60 | 291.88 | 519.87 | 1651.98 | 723.25 | 17.22 | 12.87 | 1.91 | 2.25 | 1.94 | |
| P/B Ratio | 14.87 | 11.38 | 10.19 | 7.81 | 37.31 | 12.54 | 1.03 | 3.18 | -7.34 | -105.63 | -1.09 | |
| EV/EBITDA | -68.82 | -42.09 | -26.87 | -22.45 | -72.14 | -23.06 | -0.44 | -1.42 | -0.62 | 0.17 | 0.39 | |
| EV/Revenue | 197.92 | 232.58 | 288.56 | 477.67 | 1609.88 | 691.36 | 7.04 | 9.76 | 1.48 | -0.54 | -3.57 |
Analyst Estimates & Quality
Altman Z-Score
-32.56
Distress
Piotroski F-Score
1
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $1.4M | $2.6M | $5.0M |
| Net Income | -$8.7M | -$4.7M | -$3.5M |
| EPS | $-1.10 | $-0.60 | $-0.45 |
| # Analysts (EPS) | 1 | 1 | 1 |